-
Spatial mTORC1 Inhibition Reveals Nuclear Transcriptional Ro
2026-07-08
The reference study introduces TerminaTOR, a genetically encoded mTORC1 inhibitor that can be precisely targeted to specific subcellular compartments. This approach uncovers a distinct role for nuclear mTORC1 in regulating gene transcription, providing new insights into the spatial organization of cell signaling and its implications for the PI3K/Akt/mTOR pathway.
-
Topotecan in Recurrent SCLC: Efficacy, Protocols, and Resear
2026-07-08
This article reviews the pivotal advances established by Ardizzoni et al. in evaluating topotecan for the treatment of recurrent small cell lung cancer (SCLC). The study's findings confirm topotecan's clinical utility, efficacy, and safety profile, offering essential insights for research workflows focused on apoptosis induction, tumor modeling, and therapeutic optimization in oncology.
-
Dissecting Drug Responses: Advances in In Vitro Cancer Assay
2026-07-07
Schwartz's dissertation delivers a nuanced framework for evaluating anti-cancer drug responses in vitro, distinguishing between proliferative inhibition and cell death metrics. This approach clarifies how most agents, including mTOR inhibitors, exert mixed effects, driving more accurate assay design and data interpretation for translational oncology.
-
Dihydroartemisinin: Mechanistic Insights and Translational S
2026-07-07
This article, authored from the perspective of APExBIO's scientific marketing leadership, delivers a multidimensional exploration of dihydroartemisinin—a potent Artemisia plant extract—balancing molecular mechanism, experimental validation, and translational guidance for researchers. By integrating the latest antimalarial research (including Phebestin’s nanomolar efficacy) and practical workflow considerations, the article distinguishes itself from standard product pages and guides the next wave of innovation across malaria, inflammation, and cell signaling research.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-07-06
This study introduces a localized, non-viral delivery of p21 mRNA via lipid nanoparticles as a tumor suppressor replacement strategy for bladder cancer. The approach demonstrates effective restoration of p21 function, marked tumor growth inhibition, and limited systemic exposure, offering a clinically compatible alternative to existing therapies.
-
Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi
2026-07-06
Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor that potently blocks angiogenesis and tumor growth by inhibiting VEGFR2, PDGFRβ, and FGFR1. Its nanomolar activity and high selectivity support advanced cancer research and functional assays. APExBIO supplies this reagent for preclinical research use.
-
Ridaforolimus: Applied Workflows for Cancer and Senescence A
2026-07-05
Ridaforolimus (Deforolimus, MK-8669) delivers nanomolar precision in mTOR pathway inhibition, enabling robust cancer and senescence research. This article provides actionable protocols, experimental troubleshooting, and advanced use-cases that leverage APExBIO’s trusted formulation for reproducible, high-sensitivity results.
-
GPR35-KLF5 Circuitry Orchestrates Epithelial Repair in DSS C
2026-07-04
This study uncovers a metabolic gatekeeping mechanism wherein GPR35 senses tryptophan metabolite flux to activate KLF5-dependent repair programming in intestinal epithelial cells. By elucidating how epithelial cells decode mucosal damage signals, the research advances mechanistic understanding and therapeutic targeting of ulcerative colitis.
-
Nicotinamide Adenine Dinucleotide (NAD+): Workflows & Innova
2026-07-03
Nicotinamide Adenine Dinucleotide (NAD+) from APExBIO redefines metabolic and autophagy research with high-purity, reproducibility, and workflow flexibility. Leverage the latest mechanistic insights and protocol optimizations to drive reliable, actionable results in cellular energy stress and signaling assays.
-
Demethyleneberberine Induces Senescence in NSCLC via c-Myc/H
2026-07-03
This study provides the first direct evidence that Demethyleneberberine (DMB) suppresses non-small cell lung cancer (NSCLC) cell proliferation by inducing cell cycle arrest and cellular senescence through downregulation of the c-Myc/HIF-1α pathway. These findings highlight DMB’s mechanistically distinct anti-cancer properties and offer a foundation for its application in NSCLC research models.
-
Tofacitinib (CP-690550): Protocols and Innovations in Immune
2026-07-02
Tofacitinib (CP-690550) stands out as a JAK1/JAK3-selective inhibitor, enabling immune researchers to precisely dissect cytokine signaling and mitochondrial function in inflammatory disease models. This guide translates the latest mechanistic insights into actionable experimental workflows, troubleshooting tips, and comparative advantages for immune modulation assays.
-
Trametinib (GSK1120212): From MEK Inhibition to Pain Signali
2026-07-02
Explore Trametinib (GSK1120212) as more than an oncology research tool—this article uncovers its mechanistic role as a MEK-ERK pathway inhibitor and examines new evidence for targeting sensory neuron sensitization. Discover advanced protocol guidance and practical implications for translational research.
-
TBXA2R–ERM Axis Drives TNBC Metastasis via GPCR Signaling Pa
2026-07-01
This study identifies the thromboxane A2 receptor (TBXA2R) as a pivotal activator of ezrin, radixin, and moesin (ERM) proteins, which in turn drive the motility, invasion, and metastatic colonization of triple-negative breast cancer (TNBC) cells. By mapping the signaling cascade from TBXA2R through specific G protein subfamilies and downstream kinases, the work delineates a novel axis for therapeutic targeting in metastatic cancers.
-
Bestatin (Ubenimex): Precision Aminopeptidase Inhibition Wor
2026-07-01
Bestatin (Ubenimex) stands out as a nanomolar-selective aminopeptidase inhibitor, vital for dissecting protease roles in cancer and multidrug resistance research. This guide details actionable protocols, critical troubleshooting, and the latest workflow innovations leveraging APExBIO’s trusted Bestatin.
-
Dissecting Drug Response in Cancer: Insights from In Vitro M
2026-06-30
Schwartz's dissertation advances cancer pharmacology by distinguishing between proliferative arrest and cell death in in vitro drug assays, revealing that these processes are often conflated in standard metrics. This nuanced approach has significant implications for selecting and interpreting apoptosis and proliferation assays in preclinical cancer research.